RAPT Therapeutics, Inc. Stock
Stocks
RAPT
US75382E2081
Biotechnology & Medical Research
|
Delayed
Nasdaq
08:00:00 03/03/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 58.02 USD | +0.07% |
|
-.--% | +71.30% |
| Market Cap | 1.79B 1.55B 1.45B 1.32B 2.49B 172B 2.52B 17.03B 6.68B 85.94B 6.74B 6.59B 286B | P/E 2025 * |
-
| P/E 2026 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 1.79B 1.55B 1.45B 1.32B 2.49B 172B 2.52B 17.03B 6.68B 85.94B 6.74B 6.59B 286B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
96.87% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: RAPT Therapeutics, Inc.
| 1 day | +0.07% | ||
| 6 months | +0.31% | ||
| Current year | +71.30% |
| Current year | 29.77 |  | 58.02 |
| 1 year | 10.06 | | 58.02 |
| 3 years | 5.67 | | 218.8 |
| 5 years | 5.67 | | 325.92 |
| 10 years | 5.67 | | 409.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | - | 03/03/2026 | |
Kevin Ryan
TRE | Treasurer | - | 03/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Ryan
BRD | Director/Board Member | - | 03/03/2026 |
| Director/Board Member | - | 03/03/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 3/3/26 | Tender | Director | 48,328 | 0.1744% | ||
| 3/3/26 | Tender | Director | 51,762 | 0.1868% | ||
| 30/1/26 | Free | Director | 4,956 | 0.0179% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.07% | -.--% | +394.21% | -62.38% | 1.79B | |
| +4.80% | +3.44% | +70.64% | +109.32% | 73.25B | |
| -0.21% | +14.05% | +48.97% | +90.37% | 61.95B | |
| -1.31% | -3.93% | +0.07% | +486.10% | 28.02B | |
| +5.24% | +5.65% | +56.71% | +21.30% | 24.15B | |
| +0.55% | -1.45% | -18.75% | -17.13% | 23.01B | |
| -6.00% | +6.02% | +244.39% | +430.80% | 18.35B | |
| +1.02% | +6.67% | +41.03% | -13.40% | 19.46B | |
| +3.83% | +2.65% | +21.42% | +557.58% | 15.92B | |
| +0.82% | +2.73% | +39.65% | +149.91% | 12.96B | |
| Average | +0.91% | +0.97% | +89.83% | +175.25% | 27.89B | |
| Weighted average by Cap. | +1.55% | +3.12% | +57.35% | +163.87% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | - | - |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RAPT Stock
Select your edition
All financial news and data tailored to specific country editions
